Wet Age-related Macular Degeneration (wet AMD) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

 Breaking News
  • No posts were found

Wet Age-related Macular Degeneration (wet AMD) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

May 26
21:03 2021
Wet Age-related Macular Degeneration (wet AMD) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

DelveInsight Business Research LLP
DelveInsight’s “Wet Age-related Macular Degeneration (wet AMD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Wet Age-related Macular Degeneration (wet AMD) , historical and forecasted epidemiology as well as the Wet Age-related Macular Degeneration (wet AMD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Wet Age-related Macular Degeneration (wet AMD) -Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Wet Age-related Macular Degeneration (wet AMD)  – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Wet Age-related Macular Degeneration (wet AMD) , historical and forecasted epidemiology as well as the  Wet Age-related Macular Degeneration (wet AMD)  market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

  1. Age is an important factor in the progression of the disease. In 2020, there were  214,275 cases in the age group of 61–70 years, which was the highest in any age group in the USA. This was followed by 169,164 cases in the age group of 51–60. The cases will rise to 219,912 and 173,614 in the age group of 61–70 and 51–60 years, respectively, by 2030 in the USA.

  2. In 2020, Germany had the highest population of wet-AMD among the European countries with 563,881 cases, followed by Italy, which had 419,403 cases.

  3. Among the EU5 countries, Spain had the lowest prevalent population with 300,552 cases in 2020.

  4. The prevalent population of wet AMD in Japan comprised813,974 cases in 2020

Key benefits of the report:

1. Wet Age-related Macular Degeneration (wet AMD) market report covers a descriptive overview and comprehensive insight of the Wet Age-related Macular Degeneration (wet AMD)  epidemiology and Wet Age-related Macular Degeneration (wet AMD) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. The Wet Age-related Macular Degeneration (wet AMD) market report provides insights on the current and emerging therapies.

3. Wet Age-related Macular Degeneration (wet AMD) market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Wet Age-related Macular Degeneration (wet AMD) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Wet Age-related Macular Degeneration (wet AMD) market.

Request for sample pages: https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market

Wet Age-related Macular Degeneration (wet AMD) : Overview

Wet macular degeneration is a chronic eye disorder that causes blurred vision or a blind spot in your visual field. It’s generally caused by abnormal blood vessels that leak fluid or blood into the macula (MAK-u-luh). The macula is in the part of the retina responsible for central vision

The key players involved in the Wet Age-related Macular Degeneration (wet AMD) market:

  1. Roche

  2. Chengdu Kanghong Biotech

  3. Kodiak Sciences

  4. Opthea

  5. Regenxbio

The launch of the emerging therapies is expected to significantly impact the  Wet Age-related Macular Degeneration (wet AMD)  treatment scenario in the upcoming years:-

Drug covered

  1. Faricimab

  2. Conbercept

  3. KSI-301

  4. OPT-302

  5. RGX-314

Request a free sample report @https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Wet Age-related Macular Degeneration (wet AMD) Patient Share (%) Overview at a Glance

5. Wet Age-related Macular Degeneration (wet AMD) Market Overview at a Glance

6. Wet Age-related Macular Degeneration (wet AMD) Disease Background and Overview

7. Wet Age-related Macular Degeneration (wet AMD) Epidemiology and Patient Population

8. Country-Specific Patient Population of Wet Age-related Macular Degeneration (wet AMD) 

9. Wet Age-related Macular Degeneration (wet AMD) Current Treatment and Medical Practices

10. Unmet Needs

11. Wet Age-related Macular Degeneration (wet AMD) Emerging Therapies

12. Wet Age-related Macular Degeneration (wet AMD) Market Outlook

13. Country-Wise Wet Age-related Macular Degeneration (wet AMD) Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Wet Age-related Macular Degeneration (wet AMD) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Wet Age-related Macular Degeneration (wet AMD)- Pipeline Insights, 2021

“Wet Age-related Macular Degeneration (wet AMD)- Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Wet Age-related Macular Degeneration (wet AMD) market. A detailed picture of the Wet Age-related Macular Degeneration (wet AMD) pipeline landscape is provided, which includes the disease overview and Wet Age-related Macular Degeneration (wet AMD) treatment guidelines.

Wet Age-related Macular Degeneration (wet AMD) -Epidemiology Forecast to 2030

DelveInsight’s ‘Wet Age-related Macular Degeneration (wet AMD) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Wet Age-related Macular Degeneration (wet AMD){;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Categories